{
    "nctId": "NCT04395989",
    "briefTitle": "An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.",
    "officialTitle": "An Umbrella Trial Based on Molecular Pathway for Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (FUTURE SUPER)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "TNBC - Triple-Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 139,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* ECOG Performance Status of 0-1\n* Expected lifetime of not less than three months\n* Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)\n* Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resection.\n* Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment.\n* Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)\n* Patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm\n* Have the cognitive ability to understand the protocol and be willing to participate and to be followed up.\n\nExclusion Criteria:\n\n* Symptomatic, untreated, or actively progressing CNS metastases\n* Active or history of autoimmune disease or immune deficiency\n* Active hepatitis B or hepatitis C\n* Significant cardiovascular disease\n* History of malignancy other than breast cancer within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death\n* Treatment with taxel-based chemotherapy within 6 months\n* Treatment with chemotherapy, radiotherapy,immunotherapy or surgery (outpatient clinic surgery excluded)within3 weeks prior to initiation of study treatment.\n* Pregnancy or breastfeeding, or intention of becoming pregnant during the study\n* Previous received anti-VEGFR small molecule tyrosine kinase inhibitors (e.g. famitinib, sorafenib, Sunitinib, regorafenib, etc.) for treatment of the patients .\n* A history of bleeding, any serious bleeding events.\n* Important blood vessels around tumors has been infringed and high risk of bleeding.\n* Long-term unhealing wound or incomplete healing of fracture\n* Urine protein \u22652+ and 24h urine protein quantitative \\> 1 g.\n* Arrhythmia for long-term use of anti-arrhythmic drugs and New York heart association class II or higher cardiac insufficiency",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}